Search
Spirapril
go.drugbank.com/drugs/DB01348ApprovedInvestigationalSpirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration.
Categories: Agents Acting on the Renin-Angiotensin SystemLevodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. … Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label].
Mixtures: MADOPAR 125 T, MADOPAR 125 TCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEscitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigationalto other SSRIs. … [A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigationalSulbactam is a beta (β)-lactamase inhibitor and a derivative of the basic penicillin nucleus. … [L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]
Mixtures: AMPICILLINA E SULBACTAM IBI, AMPICILLINA E SULBACTAM IBIRisperidone
go.drugbank.com/drugs/DB00734ApprovedInvestigational[L12885] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets … Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: RISPERDAL QUICLKET ® TABLETAS DE 0.5 MG, RISPERDAL QUICKLET ® TABLETAS DE 2.0 MGOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnand use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis. … [L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: EURODAN, VONAU FLASH® 8 MG TABLETA DE DESINTEGRACION ORALAmineptine
go.drugbank.com/drugs/DB04836ApprovedIllicitWithdrawnThe Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigationalTenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil]. … [A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal
Categories: Antivirals used in combination for the treatment of HIV infectionsConjugated estrogens
go.drugbank.com/drugs/DB00286ApprovedInvestigationalHowever, until 1986 official clinical trials were performed and this product was determined to be effective for the treatment of osteoporosis. … Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.
Categories: Sex Hormones and Modulators of the Genital SystemMebanazine
go.drugbank.com/drugs/DB09248ApprovedWithdrawnMebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals. … It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome